We recently compiled a list of the Why These 15 Stocks Are Skyrocketing in 2025. In this article, we are going to take a look at where Blueprint Medical (NASDAQ:BPMC) stands against the other stocks.
Stock gains always get people talking, and 2025 is no exception. Markets have moved higher for a while due to a shift toward tech innovation. The pace might slow after two years of significant returns, but investors have regained their confidence after the Stargate project was announced.
Small and mid-sized companies have started to pick up pace recently and are landing on investors’ radars as mega-cap stocks are now trading at nosebleed valuations. These companies have higher growth potential than their mega-cap rivals, and that explains the sudden surge of interest.
Smaller and mid-tier stocks did face challenges in prior years when corrections and interest rate hikes weighed on market sentiment. However, now that inflation seems more contained and Trump pushes for more rate cuts, things look even better for these mid-sized stocks.
Methodology
For this article, I screened the top-performing stocks year-to-date in the $5 billion to $20 billion market capitalization bracket. Stocks that I have covered recently will be excluded from this list.
I will also mention the number of hedge fund investors in these stocks. Why are we interested in the stocks that hedge funds invest in? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points. (see more details here).
A doctor examining a patient’s samples in a modern hospital setting.
Blueprint Medical (NASDAQ:BPMC)
Number of Hedge Fund Holders In Q3 2024: 37
Blueprint Medical (NASDAQ:BPMC) is a biopharma company that makes medicine for allergies, inflammation, and a number of cancers.
The lead product here is AYVAKIT (avapritinib). It is approved for several forms of systemic mastocytosis, and the company’s pipeline includes an oral KIT inhibitor called BLU-808, which is in development for allergic and inflammatory diseases.
BPMC stock surged in 2025 due to it updating its long-term outlook and announcing new data. It reaffirmed a large revenue opportunity for its systemic mastocytosis franchise. In January 2025, it said that AYVAKIT’s launch showed momentum and that new epidemiology data showed systemic mastocytosis was more common than previously thought. Not only that, Phase 1 results for BLU-808 came in positive.
Recent filings also show revenue gains have been solid, and losses have narrowed a lot more than previously expected. Management also guided for $475 million to $480 million in full-year 2024 AYVAKIT revenue. That means over 130% year-over-year growth. It forecasts AYVAKIT alone could reach $2 billion in annual revenue by 2030. Revenue from the overall systemic mastocytosis franchise could approach some $4 billion at its peak.
The consensus analyst price target on BPMC stock is at $126, implying 8.9% upside.
BPMC stock is up 32.57% year-to-date.
Overall BPMC ranks 7th on our list of the stocks that are skyrocketing in 2025. While we acknowledge the potential of BPMC as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than BPMC but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 10 Hottest Mid-Cap Stocks So Far in 2025 and 10 Hottest Smid-Cap Stocks So Far In 2025
Disclosure: None. This article was originally published at Insider Monkey.
